Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 1

Status

Completed 3Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 111Head & Neck 101Thoracic 38Breast 7Tumor-Agnostic 6Genitourinary 6Sarcoma 4Gynecologic 4Dermatologic 4Other neoplasm 3CNS 3Plasma cell 1

Conditions

Neoplasms 4Neoplasm Metastasis 2Carcinoma, Squamous Cell 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Cetuximab × Tumor-Agnostic × Clear all
NCT02671435 2025-07-22

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

MedImmune LLC

Phase 1/2 Active not recruiting
383 enrolled 48 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT03387111 2024-08-05

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

ImmunityBio, Inc.

Phase 1/2 Terminated
4 enrolled 14 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
15 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT00226239 2017-07-11

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

University of Pittsburgh

Phase 2 Completed
39 enrolled 10 charts
Tumor-Agnostic

Neoplasms

NCT00110357 2015-12-24

Study of Erbituxâ„¢ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Eli Lilly and Company

Phase 1 Completed
48 enrolled 22 charts
Tumor-Agnostic

Neoplasms

NCT00439517 2014-06-27

FUTURE

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
302 enrolled 18 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡